Landsittel Michael
SEC insider (Form 3/4/5 filer). CIK 0001651036. Director at Damora Therapeutics, Inc. (DMRA) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on Mar 23, 2026. Located in WALTHAM, MA.
Companies Landsittel Michael has filed insider reports for
- Damora Therapeutics, Inc. (DMRA): Director
- Blueprint Medicines Corp (BPMC): Officer, CHIEF FINANCIAL OFFICER
Landsittel Michael
CIK: 0001651036
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (16.7%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (33.3%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Mar 23, 2026DMRA
Damora Therapeutics, Inc.
AwardDirectStock Option (right to buy)
37.3K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
AwardDirect21.4K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
DispositionDirect51.1K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Tender OfferDirect43.2K shares- - Mar 5, 2025BPMC
Blueprint Medicines Corp
SaleDirect5.3K shares at avg. $88.80$469K - Mar 1, 2025BPMC
Blueprint Medicines Corp
AwardDirect11K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 23, 2026 |  DMRA Damora Therapeutics, Inc. | Award Stock Option (right to buy) | 37,313 | - | - | Direct |
| Jul 17, 2025 |  BPMC Blueprint Medicines Corp | Award | 21,353 | - | - | Direct |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | Disposition | 51,102 | - | - | Direct |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | Tender Offer | 43,175 | - | - | Direct |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | Sale | 5,284 | $88.80 | $469,219 | Direct |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | Award | 11,000 | - | - | Direct |
1-6 of 6 transactions